Imperial Innovations' portfolio company, Oxford Immunotec Global PLC (NASDAQ: OXFD), has received a Queen’s Award for Enterprise – the UK’s highest accolade in business success.
The Queen’s Awards are designed to recognise and encourage the achievements by businesses in the UK in the fields of Innovation, International Trade and Sustainable Development. The awards are made annually by Her Majesty The Queen and are only given for the highest levels of excellence demonstrated
in each category.
Oxford Immunotec received a prestigious Queen’s Award for International Trade for Continuous Achievement, based on its substantial overseas revenue growth and commercial success over six years. From 2007 to 2012, Oxford Immunotec grew its overseas earnings by greater than 1300% through expansion into markets worldwide including the United States, Japan and China. The Company’s T-SPOT®.TB test for tuberculosis is now approved for sale in over 50 countries on five continents. The T-SPOT.TB test helps to diagnose tuberculosis infection before it has progressed to full-blown disease, allowing treatment of carriers to prevent further spread of TB infection and disease.
Commenting on the Company’s achievement, Dr Peter Wrighton-Smith, Oxford Immunotec’s Chief Executive Officer, said “We are delighted and honoured to have the achievements of the Company recognized by Her Majesty. We look forward to continuing to expand the countries we serve and in continuing our strong export-led growth”.
in each category.
Oxford Immunotec received a prestigious Queen’s Award for International Trade for Continuous Achievement, based on its substantial overseas revenue growth and commercial success over six years. From 2007 to 2012, Oxford Immunotec grew its overseas earnings by greater than 1300% through expansion into markets worldwide including the United States, Japan and China. The Company’s T-SPOT®.TB test for tuberculosis is now approved for sale in over 50 countries on five continents. The T-SPOT.TB test helps to diagnose tuberculosis infection before it has progressed to full-blown disease, allowing treatment of carriers to prevent further spread of TB infection and disease.
Commenting on the Company’s achievement, Dr Peter Wrighton-Smith, Oxford Immunotec’s Chief Executive Officer, said “We are delighted and honoured to have the achievements of the Company recognized by Her Majesty. We look forward to continuing to expand the countries we serve and in continuing our strong export-led growth”.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.